<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885452</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS0003S COCOPREV</org_study_id>
    <nct_id>NCT04885452</nct_id>
  </id_info>
  <brief_title>Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation'). A Prospectvie Cohort.</brief_title>
  <official_title>Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation'). A Prospectvie Cohort.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentric, non comparative study aiming to evaluate the clinical&#xD;
      and virological evolution of high-risk patients infected with SARS-CoV-2 treated withtin the&#xD;
      framework of a cohort ATU ('Autorisation temporaire d'utilisation') delivered by the French&#xD;
      drug agency (ANSM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients hospitalized (if the patient was outpatient) or whose hospitalization was extended for complications from COVID-19 within 1 month of symtoms' onset.</measure>
    <time_frame>Month 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients hospitalized whatever the reason</measure>
    <time_frame>Month 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with an WHO score &gt;= 5</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients staying in an Intensive Care Unit in the month following symptoms' onset</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who died from COVID-19 complications and any other reason</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients presenting a adverse event and percentage of treatment discontinuation caused by those adverse events</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between first symptoms and treatment and the reasons for this delay</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological response</measure>
    <time_frame>Day 7 for ambulatory patients, Day 3, 5 and 7 for hospitalized patients</time_frame>
    <description>Percentage of virological response defined by CT&gt;=31 or negative PCR test +</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological criteria linked to the emergence of resistance</measure>
    <time_frame>from inclusion until a negative PCR test or Ct ≥31 is obtained</time_frame>
    <description>Percentage of patients included developing resistance variants, genotypic and phenotypic characterization of resistance variants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with positive anti-N and anti-S serology</measure>
    <time_frame>Day 0 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-S antibody level</measure>
    <time_frame>Day 0 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry cartography of myeloid, T-lymphocyte and B-lymphocyte response</measure>
    <time_frame>Day 0, 7 and Month 1</time_frame>
    <description>Flow cytometry cartography of myeloid (functional subtypes of monocytes and dendritic cells), T-lymphocyte (conventional T-lymphocytes by identifying naïve, memory and effector Th1, Th2, Tfh and Th17 T-lymphocytes, NK and gamma-delta T-lymphocytes, regulatory T-lymphocytes; surface and intracellular markers) and B-lymphocyte (transitional, naïve, memory T-lymphocyte with or without isotypic switching, plasmablasts) response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing of a wide range of cytokines and chemokines (IFNalpha, IFNgamma, IL-6, IL-1, IL-8, IL-15, IL-18, IL1-RA, IL-7, IL-10, CXCL10, CXCL13, CCL2 and CCL3) using the Meso Scale Discovery approach</measure>
    <time_frame>Day 0, 7 and Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological predictors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants) of the onset of complications from COVID19, hospitalization, death</measure>
    <time_frame>from inclusion until the end of the follow-up (Month 1 or Month 3)</time_frame>
    <description>Identication of clinical and biological predictors of the onset of complications from COVID19, hospitalization, death by a logistic model or survival model (RMST): the response variable is the occurrence of a complication, hospitalization, death or the average survival at 1 month on these different criteria; the covariates are the parameters at inclusion, the treatment received, the virological criteria (CT, variants) which can be considered as a time-dependent covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response</measure>
    <time_frame>from inclusion until the end of the follow-up (Month 1 or Month 3)</time_frame>
    <description>Identification of clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response by a logistic model or mixed model for repeated measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological predictors (clinical parameters, treatment received, virological criteria) of viral response (viral genotypes, emergence of resistant strains)</measure>
    <time_frame>from inclusion until the end of the follow-up (Month 1 or Month 3)</time_frame>
    <description>Identification of clinical and biological predictive factors related to the virological response (viral genotypes, emergence of resistant strains) by a logistic model: the response variable is RT-PCR negativation at D7 (or CT≥31), the covariates are the parameters at inclusion, the treatment received, the virological criteria at baseline</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Patients treated with casirivimab/imdevimab according to the ATU protocol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with bamlanivimab/etesevimab according to the ATU protocol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated according to other ATU protocols for COVID-19</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biobank</intervention_name>
    <description>Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)&#xD;
For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)&#xD;
Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)&#xD;
Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5</description>
    <arm_group_label>Patients treated according to other ATU protocols for COVID-19</arm_group_label>
    <arm_group_label>Patients treated with bamlanivimab/etesevimab according to the ATU protocol</arm_group_label>
    <arm_group_label>Patients treated with casirivimab/imdevimab according to the ATU protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with SARS-CoV-2 referred by their doctor (general practitioner,&#xD;
        specialist, SOS doctor, etc.) to a prescribing center authorized to prescribe and deliver&#xD;
        treatments benefiting from an ATU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with the criteria for COVID-19 treatment within the French compassionate&#xD;
             program (ATU)&#xD;
&#xD;
          -  Adults covered by the French social health coverage&#xD;
&#xD;
          -  Adults who signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria described in the French compassionate program (ATU)&#xD;
&#xD;
          -  Patient participating in another biomedical research with an exclusion period ongoing&#xD;
             at inclusion&#xD;
&#xD;
          -  Vulnerable patient (adults legally protected: under judicial protection, guardianship,&#xD;
             or supervision, persons deprived of their liberty)&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youri Yordanov, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Antoine Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youri Yordanov, Dr</last_name>
    <phone>01 71 97 08 69</phone>
    <email>youri.yordanov@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillaume Martin-Blondel, Pr</last_name>
    <phone>05 61 77 96 99</phone>
    <email>martin-blondel.g@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Agen-Nerac</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Albert Trinh-Duc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville</name>
      <address>
        <city>Ars-Laquenexy</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Laura Abensur Vuillaume</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Natacha Mrozek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon (HCL)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Florence Ader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>François Raffi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Aurélie Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christophe Choquet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anthony Chauvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Valérie Pourcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Youri Yordanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean-Michel Molina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Fanny Lanternnier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Cochin - Port Royal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Luc Mouthon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy St Germain en Laye</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mathilde Devaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Audrey Le Bot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Guillaume Martin-Blondel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

